REFERENCES
- Dragun D., Hoff U., Park J.K., Qun Y., Schneider W., Luft F.C., Haller H. Ischemia-reperfusion injury in renal transplantation is independent of the immunologic background. Kidney Int. 2000; 58: 2166–2177
- Schlichting C.L., Schareck W.D., Weis M. Renal ischemia-reperfusion injury: new implications of dendritic cell-endothelial cell interactions. Transplant Proc. 2006; 38: 670–673
- Helfman T., Falanga V. Gene expression in low oxygen tension. Am. J. Med. Sci. 1993; 306: 37–41
- Wang G.L., Semenza G.L. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 1995; 270: 1230–1237
- Jiang B.H., Rue E., Wang G.L., Roe R., Semenza G.L. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. 1996; 271: 17771–17778
- Jiang B.H., Zheng J.Z., Leung S.W., Roe R., Semenza G.L. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J. Biol. Chem. 1997; 272: 19253–19260
- Huang L.E., Gu J., Schau M., Bunn H.F. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 7987–7992
- Bruick R.K., McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001; 294: 1337–1340
- Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A., Tian Y.M., Masson N., Hamilton D.L., Jaakkola P., Barstead R., Hodgkin J., Maxwell P.H., Pugh C.W., Schofield C.J., Ratcliffe P.J.C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001; 107: 43–54
- Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Salic A., Asara J.M., Lane W.S., Kaelin W.G., Jr. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292: 464–468
- Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., Av Kriegsheim, Hebestreit H.F., Mukherji M., Schofield C.J., Maxwell P.H., Pugh C.W., Ratcliffe P.J. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468–472
- Jeong J.W., Bae M.K., Ahn M.Y., Kim S.H., Sohn T.K., Bae M.H., Yoo M.A., Song E.J., Lee K.J., Kim K.W. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002; 111: 709–720
- Lando D., Peet D.J., Gorman J.J., Whelan D.A., Whitelaw M.L., Bruick R.K. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002; 16: 1466–1471
- Sachs D.H. The pig as a potential xenograft donor. Vet. Immunol. Immunopathol. 1994; 43: 185–191
- Shimizu A., Meehan S.M., Kozlowski T., Sablinski T., Ierino F.L., Cooper D.K., Sachs D.H., Colvin R.B. Acute humoral xenograft rejection: destruction of the microvascular capillary endothelium in pig-to-nonhuman primate renal grafts. Lab. Invest. 2000; 80: 815–830
- D'Angelo G., Duplan E., Vigne P., Frelin C. Cyclosporin A prevents the hypoxic adaptation by activating hypoxia-inducible factor-1alpha Pro-564 hydroxylation. J. Biol. Chem. 2003; 278: 15406–15411
- Kim K.E., Jung Y.J., Yeo E.J., Chun Y.S., Park J.W. FK506, an immunosuppressive agent preserving HIF-1 activity. Immunopharmacol. Immunotoxicol. 2006; 28: 609–620
- Kim D., Kim J.Y., Koh H.S., Lee J.P., Kim Y.T., Kang H.J., Hwang W.S., Kim Y.B., Lee J.S., Ahn C. Establishment and characterization of endothelial cell lines from the aorta of miniature pig for the study of xenotransplantation. Cell Biol. Int. 2005; 29: 638–646
- Chun Y.S., Choi E., Yeo E.J., Lee J.H., Kim M.S., Park J.W. A new HIF-1 alpha variant induced by zinc ion suppresses HIF-1-mediated hypoxic responses. J. Cell Sci. 2001; 114: 4051–4061
- Maruyama K., Tomizawa S., Seki Y., Arai H., Kuroume T. Inhibition of vascular permeability factor production by cyclosporine in minimal change nephrotic syndrome. Nephron 1992; 62: 27–30
- Dumont F.J. FK506, an immunosuppressant targeting calcineurin function. Curr. Med. Chem. 2000; 7: 731–748
- Thomson A.W. FK-506--how much potential?. Immunol. Today 1989; 10: 6–9
- Mentzer R.M., JrJahania M.S., Lasley R.D. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. Multicenter FK506 Study Group. Transplantation 1998; 65: 109–113